{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T09:06:27Z","timestamp":1787735187262,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"DOI":"10.7759\/cureus.102126","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:07:01Z","timestamp":1769159221000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficiency of Human Papillomavirus (HPV) Testing in Cervical Cancer Screening and Vaccination: A Review"],"prefix":"10.7759","author":[{"given":"Shirin","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2019.09.005","article-title":"Cervical cancer screening: past, present, and future","volume":"8","author":"Bedell SL","year":"2020","unstructured":"Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical cancer screening: past, present, and future. Sex Med Rev. 2020, 8:28-37. 10.1016\/j.sxmr.2019.09.005","journal-title":"Sex Med Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2010.01269.x","article-title":"HPV infection and cervical disease: a review","volume":"51","author":"Carter JR","year":"2011","unstructured":"Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol. 2011, 51:103-8. 10.1111\/j.1479-828X.2010.01269.x","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7188.904","article-title":"Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics","volume":"318","author":"Quinn M","year":"1999","unstructured":"Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 1999, 318:904-8. 10.1136\/bmj.318.7188.904","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21955","article-title":"Overview of the European and North American studies on HPV testing in primary cervical cancer screening","volume":"119","author":"Cuzick J","year":"2006","unstructured":"Cuzick J, Clavel C, Petry KU, et al.. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006, 119:1095-101. 10.1002\/ijc.21955","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2007.07.047","article-title":"2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests","volume":"197","author":"Wright TC Jr","year":"2007","unstructured":"Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007, 197:346-55. 10.1016\/j.ajog.2007.07.047","journal-title":"Am J Obstet Gynecol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2016.11.029","article-title":"Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm","volume":"98","author":"Tota JE","year":"2017","unstructured":"Tota JE, Bentley J, Blake J, et al.. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev Med. 2017, 98:5-14. 10.1016\/j.ypmed.2016.11.029","journal-title":"Prev Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.002","article-title":"Role of HPV DNA testing in modern gynaecological practice","volume":"47","author":"Ronco G","year":"2018","unstructured":"Ronco G, Giorgi Rossi P. Role of HPV DNA testing in modern gynaecological practice. Best Pract Res Clin Obstet Gynaecol. 2018, 47:107-18. 10.1016\/j.bpobgyn.2017.08.002","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/v10120729","article-title":"Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing","volume":"10","author":"Chrysostomou AC","year":"2018","unstructured":"Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses. 2018, 10:10.3390\/v10120729","journal-title":"Viruses"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000296488.85807.b3","article-title":"Liquid compared with conventional cervical cytology: a systematic review and meta-analysis","volume":"111","author":"Arbyn M","year":"2008","unstructured":"Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008, 111:167-77. 10.1097\/01.AOG.0000296488.85807.b3","journal-title":"Obstet Gynecol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003488","article-title":"Chapter 13: Primary screening of cervical cancer with human papillomavirus tests","author":"Franco EL","year":"2003","unstructured":"Franco EL. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr. 2003, 89-96. 10.1093\/oxfordjournals.jncimonographs.a003488","journal-title":"J Natl Cancer Inst Monogr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn M","year":"2012","unstructured":"Arbyn M, Ronco G, Anttila A, et al.. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012, 30:F88-99. 10.1016\/j.vaccine.2012.06.095","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2019.105902","article-title":"Exacerbating disparities?: Cervical cancer screening and HPV vaccination","volume":"130","author":"Silver MI","year":"2020","unstructured":"Silver MI, Kobrin S. Exacerbating disparities?: Cervical cancer screening and HPV vaccination. Prev Med. 2020, 130:105902. 10.1016\/j.ypmed.2019.105902","journal-title":"Prev Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2009.06.003","article-title":"The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change","volume":"40","author":"Franco EL","year":"2009","unstructured":"Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutl\u00e9e F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res. 2009, 40:478-85. 10.1016\/j.arcmed.2009.06.003","journal-title":"Arch Med Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner J","year":"2008","unstructured":"Dillner J, Rebolj M, Birembaut P, et al.. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008, 337:a1754. 10.1136\/bmj.a1754","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00379.x","article-title":"Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and\/or high-risk HPV detection?","volume":"13","author":"Depuydt CE","year":"2009","unstructured":"Depuydt CE, Arbyn M, Benoy IH, Vandepitte J, Vereecken AJ, Bogers JJ. Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and\/or high-risk HPV detection?. J Cell Mol Med. 2009, 13:4051-60. 10.1111\/j.1582-4934.2008.00379.x","journal-title":"J Cell Mol Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: opportunity and challenge","volume":"471","author":"Wang R","year":"2020","unstructured":"Wang R, Pan W, Jin L, et al.. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020, 471:88-102. 10.1016\/j.canlet.2019.11.039","journal-title":"Cancer Lett"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki HA","year":"2011","unstructured":"Katki HA, Kinney WK, Fetterman B, et al.. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011, 12:663-72. 10.1016\/S1470-2045(11)70145-0","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2020.02.008","article-title":"Primary HPV screening for cervical cancer","volume":"65","author":"Bhatla N","year":"2020","unstructured":"Bhatla N, Singhal S. Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol. 2020, 65:98-108. 10.1016\/j.bpobgyn.2020.02.008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2011.11.003","article-title":"Human papillomavirus deoxyribonucleic acid testing in developed countries","volume":"26","author":"Bhatla N","year":"2012","unstructured":"Bhatla N, Singla S, Awasthi D. Human papillomavirus deoxyribonucleic acid testing in developed countries. Best Pract Res Clin Obstet Gynaecol. 2012, 26:209-20. 10.1016\/j.bpobgyn.2011.11.003","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer CJ","year":"2009","unstructured":"Meijer CJ, Berkhof J, Castle PE, et al.. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009, 124:516-20. 10.1002\/ijc.24010","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.12.002","article-title":"Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3","volume":"44","author":"Kotaniemi-Talonen L","year":"2008","unstructured":"Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer. 2008, 44:565-71. 10.1016\/j.ejca.2007.12.002","journal-title":"Eur J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans N","year":"2007","unstructured":"Bulkmans N, Berkhof J, Rozendaal L, et al.. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007, 370:1764-72. 10.1016\/S0140-6736(07)61450-0","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of co-testing in cervical screening","volume":"110","author":"Schiffman M","year":"2018","unstructured":"Schiffman M, Kinney WK, Cheung LC, et al.. Relative performance of HPV and cytology components of co-testing in cervical screening. J Natl Cancer Inst. 2018, 110:501-8. 10.1093\/jnci\/djx225","journal-title":"J Natl Cancer Inst"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00020","article-title":"The possible effects on socio-economic inequalities of introducing HPV testing as primary test in cervical cancer screening programs","volume":"4","author":"Giorgi Rossi P","year":"2014","unstructured":"Giorgi Rossi P, Baldacchini F, Ronco G. The possible effects on socio-economic inequalities of introducing HPV testing as primary test in cervical cancer screening programs. Front Oncol. 2014, 4:20. 10.3389\/fonc.2014.00020","journal-title":"Front Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008587","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","volume":"8","author":"Koliopoulos G","year":"2017","unstructured":"Koliopoulos G, Nyaga VN, Santesso N, et al.. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017, 8:10.1002\/14651858.CD008587","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000669","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"125","author":"Huh WK","year":"2015","unstructured":"Huh WK, Ault KA, Chelmow D, et al.. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015, 125:330-7. 10.1097\/AOG.0000000000000669","journal-title":"Obstet Gynecol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh WK","year":"2017","unstructured":"Huh WK, Joura EA, Giuliano AR, et al.. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017, 390:2143-59. 10.1016\/S0140-6736(17)31821-4","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination \u2014 updated recommendations of the advisory committee on immunization practices","volume":"65","author":"Meites E","year":"2016","unstructured":"Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination \u2014 updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016, 65:1405-8. 10.15585\/mmwr.mm6549a5","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li N","year":"2011","unstructured":"Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011, 128:927-35. 10.1002\/ijc.25396","journal-title":"Int J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5888\/pcd15.170465","article-title":"Patterns and trends in Cancer screening in the United States","volume":"15","author":"Hall IJ","year":"2018","unstructured":"Hall IJ, Tangka FK, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and trends in Cancer screening in the United States. Prev Chronic Dis. 2018, 15:E97. 10.5888\/pcd15.170465","journal-title":"Prev Chronic Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1512453","article-title":"Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature","volume":"15","author":"Hirth J","year":"2019","unstructured":"Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019, 15:146-55. 10.1080\/21645515.2018.1512453","journal-title":"Hum Vaccin Immunother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2016.07.009","article-title":"Race-specific trends in HPV vaccinations and provider recommendations: persistent disparities or social progress?","volume":"142","author":"Burdette AM","year":"2017","unstructured":"Burdette AM, Webb NS, Hill TD, Jokinen-Gordon H. Race-specific trends in HPV vaccinations and provider recommendations: persistent disparities or social progress?. Public Health. 2017, 142:167-76. 10.1016\/j.puhe.2016.07.009","journal-title":"Public Health"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106363","article-title":"Monitoring HPV vaccine impact on cervical disease: status and future directions for the era of cervical cancer elimination","volume":"144","author":"Oliveira CR","year":"2021","unstructured":"Oliveira CR, Niccolai LM. Monitoring HPV vaccine impact on cervical disease: status and future directions for the era of cervical cancer elimination. Prev Med. 2021, 144:106363. 10.1016\/j.ypmed.2020.106363","journal-title":"Prev Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials","volume":"17","author":"Arbyn M","year":"2018","unstructured":"Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines. 2018, 17:1085-91. 10.1080\/14760584.2018.1548282","journal-title":"Expert Rev Vaccines"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of realworld experience","volume":"63","author":"Garland SM","year":"2016","unstructured":"Garland SM, Kjaer SK, Mu\u00f1oz N, et al.. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of realworld experience. Clin Infect Dis. 2016, 63:519-27. 10.1093\/cid\/ciw354","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201653","article-title":"Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain","volume":"13","author":"Purri\u00f1os-Hermida MJ","year":"2018","unstructured":"Purri\u00f1os-Hermida MJ, Santiago-P\u00e9rez MI, Trevi\u00f1o M, et al.. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. PLoS One. 2018, 13:e0201653. 10.1371\/journal.pone.0201653","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy249","article-title":"The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016","volume":"218","author":"Mesher D","year":"2018","unstructured":"Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, Soldan K. The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016. J Infect Dis. 2018, 218:911-21. 10.1093\/infdis\/jiy249","journal-title":"J Infect Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet M","year":"2019","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019, 394:497-509. 10.1016\/S0140-6736(19)30298-3","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim A","year":"2007","unstructured":"Hildesheim A, Herrero R, Wacholder S, et al.. Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007, 298:743-53. 10.1001\/jama.298.7.743","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.09.008","article-title":"Therapeutic HPV vaccines","volume":"47","author":"Hancock G","year":"2018","unstructured":"Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol. 2018, 47:59-72. 10.1016\/j.bpobgyn.2017.09.008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines - a review of the first decade","volume":"146","author":"Harper DM","year":"2017","unstructured":"Harper DM, DeMars LR. HPV vaccines - a review of the first decade. Gynecol Oncol. 2017, 146:196-204. 10.1016\/j.ygyno.2017.04.004","journal-title":"Gynecol Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud PS","year":"2014","unstructured":"Naud PS, Roteli-Martins CM, De Carvalho NS, et al.. Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014, 10:2147-62. 10.4161\/hv.29532","journal-title":"Hum Vaccin Immunother"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nyg\u00e5rd M","year":"2015","unstructured":"Nyg\u00e5rd M, Saah A, Munk C, et al.. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol. 2015, 22:943-8. 10.1128\/CVI.00133-15","journal-title":"Clin Vaccine Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine","volume":"35","author":"Guevara A","year":"2017","unstructured":"Guevara A, Cabello R, Woelber L, et al.. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Vaccine. 2017, 35:5050-7. 10.1016\/j.vaccine.2017.07.017","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer AR","year":"2011","unstructured":"Kreimer AR, Rodriguez AC, Hildesheim A, et al.. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine. J Natl Cancer Inst. 2011, 103:1444-51. 10.1093\/jnci\/djr319","journal-title":"J Natl Cancer Inst"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00699-17","article-title":"Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection","volume":"91","author":"Jiang RT","year":"2017","unstructured":"Jiang RT, Wang JW, Peng S, et al.. Spontaneous and vaccine-induced clearance of Mus musculus papillomavirus 1 infection. J Virol. 2017, 91:10.1128\/JVI.00699-17","journal-title":"J Virol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton JM","year":"2011","unstructured":"Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011, 377:2085-92. 10.1016\/S0140-6736(11)60551-5","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2017-209113","article-title":"The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap","volume":"71","author":"Cameron RL","year":"2017","unstructured":"Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, Pollock KG. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap. J Epidemiol Community Health. 2017, 71:954-60. 10.1136\/jech-2017-209113","journal-title":"J Epidemiol Community Health"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen T","year":"2018","unstructured":"Luostarinen T, Apter D, Dillner J, et al.. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018, 142:2186-7. 10.1002\/ijc.31231","journal-title":"Int J Cancer"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei J","year":"2020","unstructured":"Lei J, Ploner A, Elfstr\u00f6m KM, et al.. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020, 383:1340-8. 10.1056\/NEJMoa1917338","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer SK","year":"2021","unstructured":"Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021, 113:1329-35. 10.1093\/jnci\/djab080","journal-title":"J Natl Cancer Inst"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1961","article-title":"Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-potential for prevention","volume":"8","author":"Dovey de la Cour C","year":"2019","unstructured":"Dovey de la Cour C, Guleria S, Nyg\u00e5rd M, et al.. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-potential for prevention. Cancer Med. 2019, 8:839-49. 10.1002\/cam4.1961","journal-title":"Cancer Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura EA","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, et al.. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015, 372:711-23. 10.1056\/NEJMoa1405044","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30468-1","article-title":"Changes in the prevalence of human papillomavirus following a national bivalent vaccination program in Scotland: a 7-year cross-sectional study","volume":"17","author":"Kavanaugh K","year":"2017","unstructured":"Kavanaugh K, Pollock KG, Cuschieri K, et al.. Changes in the prevalence of human papillomavirus following a national bivalent vaccination program in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017, 17:1293-1302. 10.1016\/S1473-3099(17)30468-1","journal-title":"Lancet Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444541-efficiency-of-human-papillomavirus-hpv-testing-in-cervical-cancer-screening-and-vaccination-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:07:06Z","timestamp":1769159226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444541-efficiency-of-human-papillomavirus-hpv-testing-in-cervical-cancer-screening-and-vaccination-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.102126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}